Clinical trial

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

NCT06943521

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-04-18

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2025-04-18Date precision: day

Registry last updated2025-12-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)unresolved

Non-small Cell Lung Cancer (NSCLC)unresolved

Esophageal Cancerunresolved

Gastric Cancerunresolved

Biliary Tract Cancerunresolved

Pancreatic Ductal Adenocarcinoma (PDAC)unresolved

Breast Cancerunresolved

Ovarian Cancerunresolved

Cervical Cancerunresolved

Endometrial Cancerunresolved

Prostate Cancerunresolved

Urothelial Carcinomaunresolved

Neuroendocrine Tumor (NET)unresolved

Neuroendocrine Carcinoma (NEC)unresolved

Soft Tissue Sarcomaunresolved

Nuclear Protein in Testis (NUT) Carcinomaunresolved

Interventions

Sponsors & collaborators

Tanabe Pharma America, Inc.lead sponsor

Mapped research locations

HoustonTexas, United States1 Los AngelesCalifornia, United States1 ColumbusOhio, United States1 Grand RapidsMichigan, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06943521 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.